Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a
Thomas H.R. Carlsen, Jannie Pedersen, Jannick C. Prentoe, Erick Giang, Zhen‐Yong Keck, Lotte S. Mikkelsen, Mansun Law, Steven K.H. Foung, Jens Bukh – 8 July 2014 – Human monoclonal antibodies (HMAbs) with neutralizing capabilities constitute potential immune‐based treatments or prophylaxis against hepatitis C virus (HCV). However, lack of cell culture‐derived HCV (HCVcc) harboring authentic envelope proteins (E1/E2) has hindered neutralization investigations across genotypes, subtypes, and isolates.
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
Hendrik Vilstrup, Piero Amodio, Jasmohan Bajaj, Juan Cordoba, Peter Ferenci, Kevin D. Mullen, Karin Weissenborn, Philip Wong – 8 July 2014
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
Hendrik Vilstrup, Piero Amodio, Jasmohan Bajaj, Juan Cordoba, Peter Ferenci, Kevin D. Mullen, Karin Weissenborn, Philip Wong – 8 July 2014
Acute liver allograft antibody‐mediated rejection: An inter‐institutional study of significant histopathological features
Jacqueline G. O'Leary, S. Michelle Shiller, Christopher Bellamy, Michael A. Nalesnik, Hugo Kaneku, Linda W. Jennings, Kumiko Isse, Paul I. Terasaki, Göran B. Klintmalm, Anthony J. Demetris – 6 July 2014 – Acute antibody‐mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathological characteristics have been described, specific features that could be used (1) to make a generalizable scoring system and (2) to trigger a more in‐depth analysis are needed to screen for this rare but important finding.
High early cardiovascular mortality after liver transplantation
Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones – 5 July 2014 – Cardiovascular disease (CVD) contributes to excessive long‐term mortality after liver transplantation (LT); however, little is known about early postoperative CVD mortality in the current era. In addition, there is no model for predicting early postoperative CVD mortality across centers.
Delineating definitions and risk factors for metabolic syndrome after pediatric liver transplantation
Emily Rothbaum Perito, Philip Rosenthal – 5 July 2014
Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization
Aparna Goel, Neil Mehta, Jennifer Guy, Nicholas Fidelman, Francis Yao, John Roberts, Norah Terrault – 5 July 2014 – Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down‐stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT.
Weight gain after orthotopic liver transplantation: Is nonalcoholic fatty liver disease cirrhosis a risk factor for greater weight gain?
Jasmine Kouz, Catherine Vincent, Aaron Leong, Marc Dorais, Agnès Räkel – 5 July 2014 – Posttransplant weight gain is common after orthotopic liver transplantation. We sought to determine the extent of weight gain at 5 years after transplantation in patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis versus patients with other types of cirrhosis (non‐NAFLD). We studied 126 liver transplants performed between 2005 and 2007 at Saint Luc Hospital, University of Montreal. Seventeen of the 126 patients (13.5%) had NAFLD cirrhosis.